• HOME |
  • SITE MAP |
  • CONTACT |
  • KOREAN
Product Search
since 1897 Customer visual

Help Desk

  • Dong Wha News
  • Dong Wha on TV
  • Feedback & Question
  • Voice of customer

Dong Wha News

Dong Wha Pharm’s quinolone antibacterial agent, “Zabolante,” wins at the 19th KNDA

[Date : 2018-02-28]

Our company announced that Korea’s 23rd new drug, quinolone antibacterial agent “Zabolante (zabofloxacin D-aspartate),” has won in the “new drug development category” of the 19th Korea New Drug Award (KNDA), which was organized by the Korea Drug Research Association (KDRA) on May 27.

Lim Jaekyung, the director of Dong Wha Pharm’s Synthetic Study Team, Kim Dongyeon,<br/>the CEO of KDRA, and Na Heungkyu, the director of Dong Wha Pharm Research Center

▶ Lim Jaekyung, the director of Dong Wha Pharm’s Synthetic Study Team, Kim Dongyeon,
the CEO of KDRA, and Na Heungkyu, the director of Dong Wha Pharm Research Center

Zabolante, which is a type of treatment for acute exacerbation of chronic obstructive pulmonary disease (COPD), was recognized as a new drug with high economic values, including its excellent antimicrobial activity and safety compared to existing quinolone antibiotics, convenient usage, and growth potential in the global antibiotic market.
In terms of easy usage, it provides quick relief in just a five-day medication period. Moreover, it was certified as “NET” by the Ministry of Health and Welfare, and received U.S. Food and Drug Administration (FDA)’s clinical phase 3 trial approval for community-acquired pneumonia patients.
COPD is the 7th leading cause of death in Korea (as of 2010)1, and is the second leading cause of death in the world (as of 2015)2. The treatment for COPD acute exacerbation is highly competitive in the global antibiotic market, amounting to KRW 50 trillion. Our company signed a technology transfer agreement with Pacific Beach BioSciences in 2007, and a licensing and supply agreement of Zabolante with 12 countries in the Middle East and North Africa (2016), and China (2017).
Our company won the KNDA for the second time with Zabolante this year, following the same award received in 2001 for Korea’s 3rd new drug, Milican Injection, a type of radiopharmaceuticals used in treating liver cancer.
KNDA, which is celebrating its 19th anniversary this year, is the only award in the field of new drug development in the domestic and overseas pharmaceutical industry organized by the private sector and sponsored by the government. It was established in April 1999 by the KDRA to develop the domestic pharmaceutical industry and to encourage new drug research and development. This award is sponsored by the Ministry of Scientific and Technical Information, the Ministry of Health and Welfare, and the Ministry of Trade, Industry and Energy.

List

Go to TOP

6~8F, FastFive Tower, 24, Namdaemun-ro 9-gil, Jung-gu, Seoul, 04522, KOREA

Coptright(c) Dong Wha PHARM.CO.,LTD. All Rights Reserved.